Clinical trial
Erythrocyte-Mediated Drug Delivery for the Prevention of Stent Restenosis
NCT00484965 · University of Rome Tor Vergata, Other · Unknown status
Key facts
| NCT number | NCT00484965 |
|---|---|
| Title | Erythrocyte-Mediated Drug Delivery for the Prevention of Stent Restenosis |
| Official title | Erythrocyte-Mediated Drug Delivery for the Prevention of Restenosis After Coronary Artery Stent Implantation:TROY-Study |
| Acronym | TROY |
| Lead sponsor | University of Rome Tor Vergata, Other |
| Collaborators | University of Milan |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Atherosclerosis, Acute-Phase Reaction |
| Intervention type | Procedure |
| Interventions | Coronary stenting |
| Enrollment | 100 |
| Start date | Jul 1, 2007 |
| Completion | Jan 1, 2009 |
| First posted | Jun 12, 2007 |
| Last update posted | Jun 12, 2007 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: